Trial Profile
Efficacy and safety of dose-escalating lenalidomide and dexamethasone (Rd) for unfit patients with relapsed or refractory multiple myeloma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 29 Nov 2019
Price :
$35
*
At a glance
- Drugs Dexamethasone (Primary) ; Lenalidomide (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 03 Dec 2018 Status changed from recruiting to active, no longer recruiting.
- 01 Dec 2015 New trial record